World s first intra-nasal vaccine for COVID developed by India has got approval from the Central Drugs Standard Control Organisation (CDSCO) for restricted use in emergency situations in the age group of 18 and above.
AstraZeneca Pharma India Ltd has received an Import and Market permission in Form CT-20 from the CDSCO , Directorate General of Health Services, Government of India for Dapagliflozin i.e., Forxiga® tablets of 10 mg - additional indication.
Covaxin makers Bharat Biotech also in a statement said that the targeted narrative against Covaxin is misleading and asserted that there was no external pressure to accelerate the development of Covaxin. The company clarified that the pressure was all internal to develop a safe, and effective vaccine for the Covid-19 pandemic.